Pfizer, GSK RSV shots get tepid recommendations from CDC advisory panel

The Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) has recommended that adults 60 and older—in consultation with their doctors—receive vaccines to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV). 

The thumbs-up, however, was anything but enthusiastic.

Instead of telling seniors that they should be vaccinated, the panel has said that people may get a dose of GSK’s Arexvy or Pfizer’s Abrysvo if it is right for them.